Electromed (ELMD, Financial) announced a revenue of $15.7 million for the third quarter, slightly missing expectations which were set at $15.75 million. Despite the minor shortfall, the company's President and CEO, Jim Cunniff, expressed satisfaction over ten consecutive quarters of year-over-year revenue and net income growth. Electromed's strategic initiatives include enhancing the market presence of their SmartVest Clearway therapy among healthcare providers and patients. Noteworthy efforts include launching a direct-to-consumer outreach program in partnership with the Veterans Administration across 11 cities. The company is positioning itself as a profitable and expanding small-cap medical technology firm, consistently delivering value to its shareholders.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Electromed Inc (ELMD, Financial) is $37.00 with a high estimate of $38.00 and a low estimate of $36.00. The average target implies an upside of 62.07% from the current price of $22.83. More detailed estimate data can be found on the Electromed Inc (ELMD) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Electromed Inc's (ELMD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Electromed Inc (ELMD, Financial) in one year is $18.20, suggesting a downside of 20.28% from the current price of $22.83. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Electromed Inc (ELMD) Summary page.
